Use of the biotinylated antibody DAKO-ER 1D5 to measure oestrogen receptor on cytokeratin positive cells obtained from primary breast cancer cells.

A method for the use of a biotinylated antibody (DAKO-ER 1D5) to quantify oestrogen receptors (ER) on tumour cells by flow cytometry is described. ER quantification was determined after treatment with saponin rendering cells permeable to ER antibody. Use of dual parameter labelling was performed utilizing a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18. This allowed selection of breast cancer cells of epithelial origin by gating to exclude contaminating inflammatory and stromal cells. Use of such a gating technique was seen to identify cells with a higher level of ER expression. Using QC quantum bead standards, the number of ER binding sites per cell was assessed. Results were compared with conventional ER quantification using a radio-ligand binding assay. A high degree of correlation was found between the two methods. The flow cytometric method for ER quantification described is simple, rapid, and reproducible. The assay may be of particular value in measuring ER on urgent clinical samples. Advantages of this assay over the radio-ligand binding assay include reduction in use of radio-labelled iodine compounds, a decrease in analysis time, and reduced cost and quantity of material needed for assay.

[1]  B. Angus,et al.  Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. , 1994, Cytometry.

[2]  F. Bosman,et al.  2.6 Flow cytometric steroid receptor analysis , 1992 .

[3]  F. Spyratos,et al.  Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. , 1990, Cytometry.

[4]  F. Bosman,et al.  Estrogen and progesterone receptor expression and proliferation in breast cancer cells, studied with flow cytometry. , 1990, Acta histochemica. Supplementband.

[5]  J. Hoehn,et al.  Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases. , 1989, Archives of surgery.

[6]  J. Demongeot,et al.  Image cytometry of estrogen receptors in breast carcinomas. , 1988, Cytometry.

[7]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[8]  S. Masood,et al.  The value of imprint cytology in cytochemical detection of steroid hormone receptors in breast cancer. , 1987, American journal of clinical pathology.

[9]  C. Benz,et al.  Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions. , 1985, Cytometry.

[10]  B. Barlogie,et al.  Estrogen receptor analysis by flow cytometry. , 1984, Science.

[11]  A. Howell,et al.  STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER , 1984, The Lancet.

[12]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[13]  G. Greene,et al.  Immunochemical studies of estrogen receptors. , 1984, Journal of steroid biochemistry.

[14]  H. Poulsen,et al.  Oestrogen receptor assay--limitation of the method. , 1981, European journal of cancer.

[15]  B. Alberts,et al.  Steroid receptors: elements for modulation of eukaryotic transcription. , 1976, Annual review of biochemistry.

[16]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .